CAMAGÜEY.- Used against basal cell skin cancer, the drug HeberFERON was generalized in the province for the primary health attention, after two years of application in the main hospital centers in this city.
The South polyclinic in Florida was the first to join the National Program for the Extension of the product, as commented Mérida Jiménez Lamas, its coordinator in the territory, who specified that shortly the “Joaquín de Agüero” polyclinic, located in the provincial capital, will join.
It is intended to reach also up to unities in the municipalities of Nuevitas and Guáimaro, and other two located in the city, in what is left of this year and 2020, as a part of a strategy to widen its use in the primary health level in the area, pointed out the Dermatologist expert.
With the drug – only in its type to face the Basal-cell carcinoma (BCC), the most frequent skin tumor in the world-, a little over 150 people from Camagüey were benefited in the last two years, 86 of them with full response to the treatment.
In 2018 the demarcation was the second to record the best result in this indicator, since over 40 patients sustained the complete disappearance of the lesions, after the evaluation held after 16 weeks of the use of HeberFERON.
Once again the good practice and experience in the application of the new drug are paramount for such achievements, highlighted the doctor, at the same time she emphasized the need of good training for the professionals involved in the process.
From last January and up to the date there are a little over 60 people favored by the product in the Oncological Hospital Marie Curie and the Clinical Surgery Hospital Amalia Simoni, although the service is also provided in the University Hospital Manuel Ascunce Domenech.
Developed in the Genetic Engineering and Biotechnology Center (CIGB) in Havana, the therapeutic alternative delays the tumor growth, and decreases or eliminates the BCC of any subtype, size and localization.
Another benefit is the extension of the response to the treatment at least to five years, and the reduction of the frequency of the appearance of new lesions and the performance of surgery in complex locations.
Translated by Elianna Diaz Mendieta